Category: Clinical Trials

A new Phase 3 clinical trial has launched to investigate Rina-S, a peptide-based therapeutic, as a potential maintenance treatment for patients with ovarian cancer, including primary peritoneal and fallopian tube cancers. The study will compare Rina-S—used either on its own or in combination with standard of care—to standard maintenance therapy alone following first-line platinum-based chemotherapy.

The trial is designed to enroll up to approximately 602 participants at sites around the world, reflecting the scale of international collaboration going into refining treatment options for ovarian cancer patients. Maintenance therapy after initial chemotherapy is a critical phase of care, aimed at helping keep cancer from progressing once the first round of treatment has done its work. Research like this is important because it continues to expand the toolkit oncologists may eventually have available for this stage of care.

Participants in the study can expect to be involved for an average of about four years, including roughly 16 months of active treatment and an extended follow-up period of around 29 months. This long-term design allows researchers to carefully monitor both the safety and effectiveness of the treatment over time, with regular clinic visits that include blood draws, imaging, and other standard monitoring procedures every three-week cycle.

Importantly, the study is structured to allow participants to continue receiving treatment as long as their cancer remains stable or improves and no significant safety concerns arise. This kind of adaptive, patient-centered trial design reflects a broader trend in oncology research toward giving patients continued access to potentially beneficial therapies for as long as they are helping.

Trials like this one represent meaningful progress in the search for better maintenance options following chemotherapy, a stage of treatment where effective, well-tolerated therapies can make a real difference in patients’ lives. As the study progresses, it will add to the growing body of research exploring how peptide-based treatments may complement or enhance existing cancer care standards. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer

A new phase II clinical trial is underway to investigate whether a combination of three distinct cancer-fighting agents—acalabrutinib, venetoclax, and durvalumab—can improve outcomes for patients facing Richter transformation, a rare and historically difficult-to-treat condition in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) evolves into a fast-growing lymphoma.

The trial brings together three different mechanisms of action in hopes that their combined effect may offer more robust results than any single approach alone. Acalabrutinib works by blocking enzymes that cancer cells need to grow. Venetoclax, a BCL-2 inhibitor, targets a protein that helps cancer cells survive, effectively removing one of their key defenses. Durvalumab, an immunotherapy drug, takes a different route entirely by helping the body’s own immune system recognize and attack cancer cells while also disrupting the tumor’s ability to spread.

This multi-pronged strategy reflects a broader and encouraging trend in oncology research: combining targeted therapies with immunotherapy to tackle cancers that have been historically resistant to single-agent treatments. Richter transformation has long posed a significant challenge for clinicians because of its aggressive nature and historically limited treatment options, so any research aimed at expanding the therapeutic toolkit is a welcome development for patients and families affected by this condition.

Phase II trials like this one are an important step in the broader drug development pipeline. They build on earlier safety data from phase I studies and begin to assess how effectively a treatment works in a larger patient population, while continuing to monitor safety closely. Should this trial yield promising results, it could pave the way for larger studies and, potentially, new treatment standards for patients with this rare condition.

While it will take time for full results to emerge, the initiation of this trial represents meaningful progress in the search for better therapies for rare and aggressive blood cancers. It also underscores how researchers continue to explore creative combinations of existing approved therapies to address unmet medical needs. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A newly registered clinical trial on ClinicalTrials.gov is evaluating the safety and efficacy of PTH-IA, an investigational peptide therapy designed for individuals living with Jansen’s Metaphyseal Chondrodysplasia (JMC), an exceptionally rare genetic disorder affecting only around 30 people worldwide. The condition arises from mutations in the parathyroid hormone 1 receptor (PTH1R), which cause the receptor to remain constantly active, leading to severe bone, growth, and kidney complications over a patient’s lifetime.

What makes this trial particularly encouraging is the scientific pedigree behind it. The same research team that first identified the JMC-causing PTH1R mutations more than two decades ago has spent years studying how to counteract the receptor’s overactivity. Their work led to the discovery of peptide ligands that act as inverse agonists, meaning they can actually suppress the excessive signaling caused by the mutant receptor rather than simply blocking normal signaling. Early laboratory and animal studies have shown that these inverse agonist ligands can reduce the abnormal cAMP signaling at the heart of the disease.

PTH-IA itself is a 30-amino acid peptide derived from parathyroid hormone-related peptide (PTHrP), engineered with specific modifications to target the overactive receptor pathway. Because JMC currently has no approved treatments, patients and families have had to rely solely on managing symptoms and complications, often through repeated surgeries for fractures and skeletal deformities. A therapy that addresses the underlying molecular cause, rather than just the downstream effects, represents a meaningful shift in how this disease might eventually be managed.

While JMC is extremely rare, the approach being tested here reflects a broader and very promising trend in peptide science: using precisely engineered peptides to correct specific receptor malfunctions at the molecular level. Success in a condition like JMC could also offer valuable insights into related PTH1R signaling pathways that are relevant to more common bone and mineral disorders.

This trial is an important step for a patient community that has long awaited a dedicated therapeutic option. As with all early-phase clinical research, results will take time, and safety and efficacy have yet to be established in humans. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Safety and Efficacy of PTH-IA

A new clinical trial listed on ClinicalTrials.gov is set to examine whether ziltivekimab, an investigational anti-inflammatory therapy, may offer benefits for people living with heart failure who also show signs of inflammation. The study will compare ziltivekimab to a placebo, with participants randomly assigned to one group or the other, ensuring a fair and scientifically rigorous comparison.

Heart failure is a complex condition, and researchers have increasingly recognized that inflammation may play a meaningful role in how the disease progresses. By specifically studying participants who have elevated inflammatory markers alongside heart failure, this trial represents a thoughtful, targeted approach to understanding whether addressing inflammation could translate into meaningful health benefits for patients.

The study is expected to run for approximately one year and four months, allowing researchers time to gather meaningful data on how participants respond over an extended period. This kind of long-term, carefully controlled research is an encouraging sign of the rigorous science being applied to new potential therapies in the cardiovascular space.

It’s worth noting that ziltivekimab is not yet approved for use anywhere in the world, and doctors cannot currently prescribe it. This trial is an important step in the broader research process that determines whether a new medicine is both safe and effective before it can move toward potential approval. Studies like this one are foundational to medical progress, helping scientists and clinicians better understand new treatment possibilities for people facing serious health conditions.

The heart failure community, along with researchers and clinicians, will likely watch the results of this study with interest, as it could contribute valuable insights into the relationship between inflammation and cardiovascular health. As with all investigational treatments, patience and rigorous science are essential before any conclusions can be drawn.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Exciting new data from clinical trials of retatrutide, an investigational triple-agonist peptide, demonstrates weight loss of up to 20.8% in patients managing both obesity and type 2 diabetes—two conditions that have historically been challenging to address simultaneously with a single treatment approach.

Retatrutide works by targeting three distinct hormone receptors involved in metabolism and appetite regulation, a mechanism that builds on the success of earlier dual-agonist peptides. The reported results are particularly encouraging because patients with type 2 diabetes often experience more modest weight loss responses to treatment compared to those without diabetes, due to the complex interplay between blood sugar regulation and body weight. Achieving over 20% weight reduction in this population represents a meaningful step forward for a group that frequently faces limited options.

These findings add to a growing body of evidence suggesting that next-generation peptide therapies may offer substantial benefits for people managing the dual burden of obesity and diabetes. Effective weight management in this population can contribute to improved blood sugar control, reduced strain on the cardiovascular system, and better overall metabolic health. The scale of weight loss reported here is notable when compared to many existing treatment options, highlighting the potential of multi-receptor targeting as a therapeutic strategy.

Researchers and clinicians continue to study retatrutide’s safety profile and long-term outcomes as part of its ongoing clinical development. The peptide field has seen rapid innovation in recent years, with triple-agonist compounds like retatrutide representing the latest evolution in a lineage of treatments that began with single-hormone therapies and progressed to dual-action peptides. Continued trial progress offers hope for more personalized and effective treatment options for people living with both obesity and type 2 diabetes.

As research progresses, the peptide community will be watching closely for additional data on durability of results and broader patient populations. This is for informational purposes only and not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D – AJMC

A new international clinical trial has begun evaluating AUBE00, an investigational therapy being studied for its potential to treat locally advanced or metastatic solid tumors. Registered on ClinicalTrials.gov, this first-in-human, open-label Phase I study marks an important early step in exploring the compound’s ability to help patients facing difficult-to-treat cancers.

The trial will enroll approximately 90 to 130 participants across multiple centers and countries, allowing researchers to gather diverse data on how the therapy performs in real-world clinical settings. Investigators will assess key factors including safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary signs of anti-tumor activity. This comprehensive early-phase design reflects a thorough, methodical approach to understanding how AUBE00 behaves in the human body before any larger efficacy trials are considered.

Phase I trials like this one are foundational to the drug development process. They provide crucial information about dosing, safety margins, and how the body processes a new treatment. For patients with advanced solid tumors, participation in such trials can offer access to novel therapeutic approaches when standard treatment options may be limited, while also contributing valuable scientific knowledge that could benefit future patients.

The multinational, multicenter design of this study is particularly encouraging, as it suggests a coordinated global effort to accelerate understanding of this investigational therapy. Collaboration across research sites often speeds up recruitment and allows for more robust data collection, which can help bring promising treatments closer to patients who need them.

While it will take time before results from this study are available, the initiation of this trial represents a hopeful step forward in oncology research. True North Labs will continue to follow developments in this space and share updates as they emerge. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Study of AUBE00 in Patients With Solid Tumors